CAM
REGN icon

Clarity Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Clarity Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$3.89K – 226
2026
Q1 		$3.89K Hold
5
– – ﹤0.01% 252
2025
Q4 		$3.88K Hold
5
– – ﹤0.01% 215
2025
Q3 		$2.83K Hold
5
– – ﹤0.01% 220
2025
Q2 		$2.63K Hold
5
– – ﹤0.01% 226
2025
Q1 		$3.18K Hold
5
– – ﹤0.01% 192
2024
Q4 		$3.56K Hold
5
– – ﹤0.01% 189
2024
Q3 		$5.26K Hold
5
– – ﹤0.01% 163
2024
Q2 		$5.25K Hold
5
– – ﹤0.01% 155
2024
Q1 		$4.81K Hold
5
– – ﹤0.01% 163
2023
Q4 		$4.39K Buy
+5
New +$4.12K ﹤0.01% 166

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Clarity Asset Management's REGN Position: Q2 2026 in Review

Clarity Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 5 shares — an estimated $3.89K sold.

Clarity Asset Management first reported a position in REGN in Q4 2023 and held it in 10 quarters. The position peaked at $5.26K in Q3 2024. 336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Clarity Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Clarity Asset Management sold 5 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.89K.
  • Clarity Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • Clarity Asset Management's Regeneron Pharmaceuticals position peaked at $5.26K in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Clarity Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.